Cancer Support Community Advocates for Patients and Families in Washington, D.C.

WASHINGTON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- The Cancer Support Community, in partnership with leading cancer advocacy and community health care organizations, is participating today in a series of events to explore topics and challenges in community oncology and to advocate for the needs of patients on Capitol Hill.

Kim Thiboldeaux, CEO of the Cancer Support Community, will moderate a panel discussion at the White House this morning as part of an event to highlight the policy priorities of community cancer centers. In the afternoon, advocates will assemble on Capitol Hill for a briefing that will include a panel discussion and remarks from patients, medical experts, the Centers for Medicare and Medicaid Services, and the Cancer Moonshot Task Force, convened by Vice President Joe Biden in 2016 to increase research funding and accelerate cancer discoveries. Sen. Jon Tester and Reps. Diana DeGette, & Fred Upton are also planning to give remarks.

"The Cancer Support Community is proud and honored to participate in this important day for community cancer advocacy, and we applaud the White House and the Cancer Moonshot initiative for their continued commitment to advancing the needs of cancer patients and their families," said Thiboldeaux.

The Cancer Support Community is joined by the American Cancer Society Cancer Action Network, the Association of Community Cancer Centers, the Community Oncology Alliance, McKesson Specialty Health, Sarah Cannon, The US Oncology Network, and Whitman-Walker Health in today's events.

The morning's event at the White House will be livestreamed beginning at 8:00 a.m. at
For more information on the Cancer Support Community's involvement in the Cancer Moonshot initiative and other cancer advocacy efforts, please visit
About the Cancer Support Community
As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. CSC achieves its mission through three areas: direct service delivery, research and advocacy. The organization includes an international network of Affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral and survivorship research. CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation. For more information, please call the toll-free Cancer Support Helpline at 888-793-9355, or visit

CONTACT: Emily Martin
Wednesday, January 11, 2017 - 10:58

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.